Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
International Journal of Obesity (2005)
|
December 5, 2013
Cost effectiveness of primary care referral to a commercial provider for weight loss treatment, relative to standard care: a modelled lifetime analysis
N R Fuller, H Carter, D Schofield, et al.
Diabetes Care
|
May 20, 1999
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
R Moses, R Slobodniuk, S Boyages, et al.
Clinical Obesity
|
August 13, 2013
Trends in overweight and obesity over 22 years in a large adult population: the HUNT Study, Norway
K Midthjell, C M Y Lee, A Langhammer, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 24, 2004
Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes
S R Heller, S Colagiuri, S Vaaler, et al.
Journal of Internal Medicine
|
February 27, 2008
The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study
A J Cameron, D J Magliano, P Z Zimmet, et al.
Journal of Paediatrics and Child Health
|
May 31, 2025
Population Incidence and Burden of Juvenile Idiopathic Arthritis on Australian Health System: Data Linkage Study
S J Lain, L Ivancic, J Chaitow, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
March 26, 2009
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M Marre, J Shaw, M Brändle, et al.
Internal Medicine Journal
|
May 7, 2015
Cost to government and society of chronic kidney disease stage 1-5: a national cohort study
M L R Wyld, C M Y Lee, X Zhuo, et al.
Diabetologia
|
February 17, 2010
The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study
A P Kengne, A Patel, S Colagiuri, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
October 4, 2011
Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial
G-D Batty, Q Li, R Huxley, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
International Journal of Obesity (2005)
|
December 5, 2013
Cost effectiveness of primary care referral to a commercial provider for weight loss treatment, relative to standard care: a modelled lifetime analysis
N R Fuller, H Carter, D Schofield, et al.
Diabetes Care
|
May 20, 1999
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
R Moses, R Slobodniuk, S Boyages, et al.
Clinical Obesity
|
August 13, 2013
Trends in overweight and obesity over 22 years in a large adult population: the HUNT Study, Norway
K Midthjell, C M Y Lee, A Langhammer, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 24, 2004
Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes
S R Heller, S Colagiuri, S Vaaler, et al.
Journal of Internal Medicine
|
February 27, 2008
The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study
A J Cameron, D J Magliano, P Z Zimmet, et al.
Journal of Paediatrics and Child Health
|
May 31, 2025
Population Incidence and Burden of Juvenile Idiopathic Arthritis on Australian Health System: Data Linkage Study
S J Lain, L Ivancic, J Chaitow, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
March 26, 2009
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M Marre, J Shaw, M Brändle, et al.
Internal Medicine Journal
|
May 7, 2015
Cost to government and society of chronic kidney disease stage 1-5: a national cohort study
M L R Wyld, C M Y Lee, X Zhuo, et al.
Diabetologia
|
February 17, 2010
The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study
A P Kengne, A Patel, S Colagiuri, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
October 4, 2011
Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial
G-D Batty, Q Li, R Huxley, et al.
Page
of 9